Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 31;33(6):694–707. doi: 10.21147/j.issn.1000-9604.2021.06.06

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2021Chinese Journal of Cancer Research. All rights reserved.

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

Enrichment of TICs in recurrent tissues after IRFA treatment. (A) Representative H&E staining (a,b) and CECT images of primary HCC (white arrow in c) and recurrent HCC (red arrow in d), * in d indicating the necrotic lesion of RFA treatment; (B) Overall survival rate for primary and recurrent HCC patients after RFA was compared using Kaplan-Meier analysis (P<0.05); (C) Immunofluorescence staining was used for detecting the expression of CD133⁺ and EpCAM⁺ TICs in primary and recurrent HCC tumors. Samples were obtained in seven patients with both primary tumors and recurrent tumors. Positive cells were stained with green signal; nuclei were stained with DAPI (blue). The bar graph in the right indicates the proportion of Ki-67⁺ and CD34⁺ cells as . TIC, tumor-initiating cell; IRFA, insufficient radiofrequency ablation; H&E, hematoxylin & eosin; CECT, contrast-enhanced computed tomography; HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; EpCAM, epithelial cell adhesion molecule; DAPI, 4’,6-diamidino-2-phenylindole.^***, P<0.001.

Inline graphic — Enrichment of TICs in recurrent tissues after IRFA treatment. (A) Representative H&E staining (a,b) and CECT images of primary HCC (white arrow in c) and recurrent HCC (red arrow in d), * in d indicating the necrotic lesion of RFA treatment; (B) Overall survival rate for primary and recurrent HCC patients after RFA was compared using Kaplan-Meier analysis (P<0.05); (C) Immunofluorescence staining was used for detecting the expression of CD133⁺ and EpCAM⁺ TICs in primary and recurrent HCC tumors. Samples were obtained in seven patients with both primary tumors and recurrent tumors. Positive cells were stained with green signal; nuclei were stained with DAPI (blue). The bar graph in the right indicates the proportion of Ki-67⁺ and CD34⁺ cells as . TIC, tumor-initiating cell; IRFA, insufficient radiofrequency ablation; H&E, hematoxylin & eosin; CECT, contrast-enhanced computed tomography; HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; EpCAM, epithelial cell adhesion molecule; DAPI, 4’,6-diamidino-2-phenylindole.^***, P<0.001.